Expanding Into Clinical Trials

DSP

Why More Product Upstream Creates New Pressure Downstream

Pharma's Almanac

Enzymatic Synthesis

Transforming Enzymatic Processes into Commercial-Scale Manufacturing

Kohei Mori

Kaneka

Pathfinder

Platform Development vs. Molecule-Specific Process Development: Which Strategy Is Better for Biologics?

Nice Insight

Oncolytic Viruses

Manufacturing Oncolytic Viruses: Where Complexity Demands Experience

Mathias Kahl

IDT Biologika

MRD

Measurable Residual Disease Moves Deeper Into Hematologic Cancer Development

Pharma's Almanac

Biosimilars

The Global Division of Labor Behind the Coming Oncology Biosimilar Wave

Pharma's Almanac

Pathfinder

Enzymatic Synthesis vs. Fermentation for Biomanufacturing: Which Production Strategy Is Better?

Nice Insight

Single-Use

The Changing Economics of Single-Use Biomanufacturing

Pharma's Almanac

Biologics Platform

Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities

Mathias Kahl

IDT Biologika

CDMO Governance

The Governance Gap: Why Good CDMO Partnerships Still Fail

Pharma's Almanac